Sanofi 6-K Report: Clinical Study Update on E. Coli Vaccine - February 2025

Here are the key insights extracted from the provided section of the financial report:

1. Filing Type and Date: The document is a 6-K report filed by Sanofi, with the report dated February 13, 2025.
2. Company Information:

• Name: Sanofi
• Address: 46, avenue de la Grande Armée, 75017 Paris, France
• Commission File Number: 001-31368

3. Regulatory Compliance: The filing is made pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, indicating compliance with SEC regulations as a foreign private issuer.
4. Content of the Report: The report includes a press release (Exhibit 99.1) which provides an update on a clinical study related to an extraintestinal pathogenic E. coli vaccine. This indicates ongoing research and development efforts in the area of vaccine development, which could be of interest to investors and stakeholders.
5. Exhibit Index: The document references Exhibit 99.1, which contains the details of the press release dated February 13, 2025.
6. Signature: The report is signed by Alexandra Roger, who holds the position of Head of Legal Corporate & Finance, indicating that the information is officially recognized by a senior company officer.

These points capture the essential elements of the filing, including corporate identity, regulatory context, and the focus of the company's ongoing clinical research, which may impact future performance and investor interest.